paroxetine has been researched along with methoxyhydroxyphenylglycol in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (28.57) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alling, C; Dalgaard, L; Lundmark, J; Manniche, PM; Wålinder, J | 1 |
Goodnick, PJ; Henry, J; Kumar, A | 1 |
Nakamura, J; Okamoto, K; Shinkai, K; Ueda, N; Yoshimura, R | 1 |
Goto, M; Kaji, K; Kakihara, S; Nakamura, J; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R | 1 |
Hori, H; Mitoma, M; Miyamoto, K; Nakamura, J; Sugita, A; Ueda, N; Umene, W; Yoshimura, R | 1 |
Castro, WL; Delgado, PL; El Khoury, A; Mathé, AA; Misiaszek, J; Moreno, FA; Palmer, C; Parkinson, D; Wright, R | 1 |
Amianto, F; Brambilla, F; Dalle Grave, R; Fassino, S | 1 |
4 trial(s) available for paroxetine and methoxyhydroxyphenylglycol
Article | Year |
---|---|
Risperidone in the treatment of psychotic depression.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Time Factors | 2006 |
Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients.
Topics: Adult; Aged; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Cotinine; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Methoxyhydroxyphenylglycol; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Smoking; Tobacco Use Disorder; Treatment Outcome | 2007 |
CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls.
Topics: Adult; Analysis of Variance; Case-Control Studies; Chromatography, High Pressure Liquid; Circadian Rhythm; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; Electrochemistry; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Indoles; Male; Methoxyhydroxyphenylglycol; Middle Aged; Neurochemistry; Neuropeptide Y; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Tryptophan; Young Adult | 2010 |
Lack of efficacy of psychological and pharmacological treatments of disorders of eating behavior: neurobiological background.
Topics: Administration, Oral; Adult; Analysis of Variance; Anorexia Nervosa; Antipsychotic Agents; Benzodiazepines; Bulimia Nervosa; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Olanzapine; Paroxetine; Psychotherapy, Brief; Serotonin Plasma Membrane Transport Proteins; Treatment Failure | 2014 |
3 other study(ies) available for paroxetine and methoxyhydroxyphenylglycol
Article | Year |
---|---|
The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients.
Topics: Aged; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyphenylglycol; Neurotransmitter Agents; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors | 1994 |
Neurochemistry and paroxetine response in major depression.
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Middle Aged; Paroxetine; Personality Inventory; Serotonin | 1995 |
Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment.
Topics: Adult; Aged; Biomarkers; Cyclopropanes; Depressive Disorder; Female; Homovanillic Acid; Hospitals, University; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Milnacipran; Paroxetine; Patient Selection; Selective Serotonin Reuptake Inhibitors | 2004 |